#Accro_Bioscience
Accro Bioscience's AC-101 Tablets Join NMPA's Rare Disease Development Initiative#China#Suzhou#AC-101#Accro_Bioscience#Blau_syndrome
Accro Bioscience's AC-101 Tablets Join NMPA's Rare Disease Development Initiative
Accro Bioscience's AC-101 has been included in NMPA's innovative program for rare diseases, aiming to enhance drug development for Blau syndrome.
third-news.com
September 14, 2026 at 2:07 AM
Accro Bioscience Secures IND Approval for Vitiligo Treatment Trial in China#China#Suzhou#Fosun_Pharma#AC-201#Accro_Bioscience
Accro Bioscience Secures IND Approval for Vitiligo Treatment Trial in China
Accro Bioscience has received clearance from China's NMPA for their Phase II/III trial on AC-201, targeting non-segmental vitiligo treatment.
third-news.com
September 8, 2026 at 12:31 PM
Accro Bioscience to Unveil Promising Phase Ib AC-101 Data at UEG Week 2026 in Barcelona#Spain#Ulcerative_Colitis#Barcelona#AC-101#Accro_Bioscience
Accro Bioscience to Unveil Promising Phase Ib AC-101 Data at UEG Week 2026 in Barcelona
Accro Bioscience will present vital Phase Ib data for AC-101, a selective RIPK2 inhibitor aimed at treating moderate-to-severe ulcerative colitis, at UEG Week 2026.
third-news.com
August 13, 2026 at 11:11 AM